The Ensign Group Acquires Post-Acute Care Campus in Arizona

The Ensign Group, Inc., the parent company of the EnsignTM group of companies, which provide skilled nursing and assisted living services, physical, occupational and speech therapies and other rehabilitative and healthcare services, announced today (August 3, 2020) that it acquired the real estate and operations of a post-acute care retirement campus located in Tempe, AZ.

The acquisition was effective August 1, 2020.  The acquisition includes Tempe Post Acute, a 62-bed skilled nursing facility and Desert Marigold Senior Living of Tempe a senior living center with 72 assisted living beds and 90 independent living units.

“We are very excited to add this well-respected healthcare campus to our mature operations in the greater Phoenix market” said Barry Port, Ensign’s Chief Executive Officer. “As our first transaction since the COVID pandemic arrived at our door steps, our local leadership team in Arizona has taken extra precautions and have implemented a care plan to meet the needs of patients while closely following local and state guidelines.   We have full confidence in our team’s ability to add this operation in the midst of a pandemic and look forward to working with our new team,” he added.

“This is a unique time to add an operation but our local team of clinical and operational leaders are amongst our most experienced transition teams that have participated in many acquisitions in Arizona,” said Forrest Peterson, President of Bandera Healthcare LLC, Ensign’s Arizona-based subsidiary.  “We are also very impressed with the talented group of caregivers at these operations and look forward to working together to enhance the clinical outcomes and to take this operation to new heights,” he added.

These acquisitions bring Ensign’s growing portfolio to 226 healthcare operations, 24 of which also include assisted living operations, across thirteen states.  Ensign owns the real estate at 92 healthcare operations.  Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, assisted living and other healthcare related businesses throughout the United States.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”